Oncology and Hematology

33-48 of 70

• 

  RestartResume

  The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC

  RestartResume

  The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC

  MinuteCE®

  The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC

  Harry Yoon, MD; Jaffer Ajani, MD

  0.75 program credits

  • 

    

    Harry Yoon, MD

  • 

    

    Jaffer Ajani, MD

  0.75 program credits

• 

  RestartResume

  ICI Combination Regimens for First-Line Treatment of Metastatic ESCC

  RestartResume

  ICI Combination Regimens for First-Line Treatment of Metastatic ESCC

  MinuteCE®

  ICI Combination Regimens for First-Line Treatment of Metastatic ESCC

  Harry Yoon, MD; Jaffer Ajani, MD

  0.75 program credits

  • 

    

    Harry Yoon, MD

  • 

    

    Jaffer Ajani, MD

  0.75 program credits

• 

  MinuteCE®

  Differentiating First-Line Treatment Selection: Combination Immunotherapy and Chemotherapy Regimens for Metastatic ESCC

  Harry Yoon, MD; Jaffer Ajani, MD

  0.75 credits 7 episodes

  • 

    

    Harry Yoon, MD

  • 

    

    Jaffer Ajani, MD

  0.75 credits 7 episodes

• 

  RestartResume

  The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC

  RestartResume

  The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC

  MinuteCE®

  The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC

  Harry Yoon, MD

  0.75 program credits

  • 

    

    Harry Yoon, MD

  0.75 program credits

• 

  RestartResume

  Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC

  RestartResume

  Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC

  MinuteCE®

  Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC

  Harry Yoon, MD; Jaffer Ajani, MD

  0.75 program credits

  • 

    

    Harry Yoon, MD

  • 

    

    Jaffer Ajani, MD

  0.75 program credits

• 

  RestartResume

  Differential Diagnosis of Indolent Systemic Mastocytosis

  RestartResume

  Differential Diagnosis of Indolent Systemic Mastocytosis

  MinuteCE®

  Differential Diagnosis of Indolent Systemic Mastocytosis

  Nathan A. Boggs, MD; Tracy George, MD

  0.50 program credits

  • 

    

    Nathan A. Boggs, MD

  • 

    

    Tracy George, MD

  • 

    

    Lindsay Rein, MD

  0.50 program credits

• 

  RestartResume

  Is it Nonresponsive/Progressive ISM?

  RestartResume

  Is it Nonresponsive/Progressive ISM?

  MinuteCE®

  Is it Nonresponsive/Progressive ISM?

  Nathan A. Boggs, MD; Tracy George, MD

  0.50 program credits

  • 

    

    Nathan A. Boggs, MD

  • 

    

    Tracy George, MD

  • 

    

    Lindsay Rein, MD

  0.50 program credits

• 

  MinuteCE®

  The Pathologist Perspective: Identifying Systemic Mastocytosis in the Community

  Nathan A. Boggs, MD; Tracy George, MD

  0.50 credits 4 episodes

  • 

    

    Nathan A. Boggs, MD

  • 

    

    Tracy George, MD

  • 

    

    Lindsay Rein, MD

  0.50 credits 4 episodes

• 

  RestartResume

  Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia

  RestartResume

  Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia

  MinuteCE®

  Accurate Diagnosis and Management of Hereditary Alpha Tryptasemia

  Nathan A. Boggs, MD; Tracy George, MD

  0.50 program credits

  • 

    

    Nathan A. Boggs, MD

  • 

    

    Tracy George, MD

  • 

    

    Lindsay Rein, MD

  0.50 program credits

• 

  RestartResume

  Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm

  RestartResume

  Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm

  MinuteCE®

  Diagnosis and Treatment of Systemic Mastocytosis With an Associated Hematologic Neoplasm

  Nathan A. Boggs, MD; Tracy George, MD

  0.50 program credits

  • 

    

    Nathan A. Boggs, MD

  • 

    

    Tracy George, MD

  • 

    

    Lindsay Rein, MD

  0.50 program credits

• 

  RestartResume

  Understanding CNS Lesions in HER2+ Metastatic Breast Cancer

  RestartResume

  Understanding CNS Lesions in HER2+ Metastatic Breast Cancer

  MinuteCE®

  Understanding CNS Lesions in HER2+ Metastatic Breast Cancer

  Sarah Sammons, MD

  1.00 program credit

  • 

    

    Sarah Sammons, MD

  1.00 program credit

• 

  RestartResume

  Systemic Management of Brain Metastases in HER2+ BC: Emerging Strategies and Treatment Approaches

  RestartResume

  Systemic Management of Brain Metastases in HER2+ BC: Emerging Strategies and Treatment Approaches

  MinuteCE®

  Systemic Management of Brain Metastases in HER2+ BC: Emerging Strategies and Treatment Approaches

  Carey Anders, MD, FASCO

  1.00 program credit

  • 

    

    Carey Anders, MD, FASCO

  1.00 program credit

• 

  RestartResume

  HER2-Targeted TKI Combinations in Second-Line and Beyond MBC 

  RestartResume

  HER2-Targeted TKI Combinations in Second-Line and Beyond MBC 

  MinuteCE®

  HER2-Targeted TKI Combinations in Second-Line and Beyond MBC 

  Sarah Sammons, MD

  1.00 program credit

  • 

    

    Sarah Sammons, MD

  1.00 program credit

• 

  RestartResume

  Optimizing Treatment Selection for HER2+ Breast Cancer Patients with Brain Metastases

  RestartResume

  Optimizing Treatment Selection for HER2+ Breast Cancer Patients with Brain Metastases

  MinuteCE®

  Optimizing Treatment Selection for HER2+ Breast Cancer Patients with Brain Metastases

  Carey Anders, MD, FASCO; Sarah Sammons, MD

  1.00 program credit

  • 

    

    Carey Anders, MD, FASCO

  • 

    

    Sarah Sammons, MD

  1.00 program credit

• 

  RestartResume

  Leveraging Clinical Data: HER2-Targeted ADCs in Second-Line and Beyond MBC 

  RestartResume

  Leveraging Clinical Data: HER2-Targeted ADCs in Second-Line and Beyond MBC 

  MinuteCE®

  Leveraging Clinical Data: HER2-Targeted ADCs in Second-Line and Beyond MBC 

  Carey Anders, MD, FASCO

  1.00 program credit

  • 

    

    Carey Anders, MD, FASCO

  1.00 program credit

• 

  RestartResume

  Differentiating Agents in the Expanding HER2-Targeted Arsenal for Metastatic Breast Cancer   

  RestartResume

  Differentiating Agents in the Expanding HER2-Targeted Arsenal for Metastatic Breast Cancer   

  MinuteCE®

  Differentiating Agents in the Expanding HER2-Targeted Arsenal for Metastatic Breast Cancer   

  Carey Anders, MD, FASCO; Sarah Sammons, MD

  1.00 program credit

  • 

    

    Carey Anders, MD, FASCO

  • 

    

    Sarah Sammons, MD

  1.00 program credit